المؤلفون: Gazzola, Anna, Navari, Mohsen, Mannu, Claudia, Donelli, Riccardo, Etebari, Maryam, Piccaluga, Pier Paolo

المصدر: Cancers; Sep2023, Vol. 15 Issue 18, p4624, 18p

مصطلحات موضوعية: DIAGNOSIS of blood diseases, LYMPHATIC disease diagnosis, SEQUENCE analysis, PREDICTIVE tests, EVIDENCE-based medicine, CAPILLARY electrophoresis, GENES, RESEARCH funding, DESCRIPTIVE statistics, SENSITIVITY & specificity (Statistics), CYTOLOGY, PHENOTYPES

مستخلص: Simple Summary: Clonality testing and somatic hypermutation analysis performed on B-cell receptor encoding genes are the most widely used molecular assays for lymphoma diagnostics. Currently, PCR-based methods standardized by the BIOMED2 consortium are regarded as the gold standard. In the last few years, new approaches based on next-generation sequencing (NGS) have been proposed and validated in phase I–II studies. Here, we present the first phase III diagnostic accuracy study, evaluating an NGS-based protocol (LymphoTrack^® IGH assay, and LymphoTrack^® IGH somatic hypermutation assay) compared to the gold standard. We formally documented a high diagnostic accuracy providing a clinical validation of the assays. Background: Multiplex PCR based on consensus primers followed by capillary electrophoresis and Sanger sequencing are considered as the gold standard method for the evaluation of clonality and somatic hypermutation in lymphoid malignancies. As an alternative, the next-generation sequencing (NGS) of immune receptor genes has recently been proposed as a solution, due to being highly effective and sensitive. Here, we designed a phase III diagnostic accuracy study intended to compare the current gold standard methods versus the first commercially available NGS approaches for testing immunoglobulin heavy chain gene rearrangements. Methods: We assessed IGH rearrangements in 68 samples by means of both the NGS approach (LymphoTrack^® IGH assay, and LymphoTrack^® IGH somatic hypermutation assay, run on Illumina MiSeq) and capillary electrophoresis/Sanger sequencing to assess clonality and somatic hypermutations (SHM). Results: In comparison to the routine capillary-based analysis, the NGS clonality assay had an overall diagnostic accuracy of 96% (63/66 cases). Other studied criteria included sensitivity (95%), specificity (100%), positive predictive value (100%) and negative predictive value (75%). In discrepant cases, the NGS results were confirmed by a different set of primers that provided coverage of the IGH leader sequence. Furthermore, there was excellent agreement of the SHM determination with both the LymphoTrack^® FR1 and leader assays when compared to the Sanger sequencing analysis (84%), with NGS able to assess the SHM rate even in cases where the conventional approach failed. Conclusion: Overall, conventional Sanger sequencing and next-generation-sequencing-based clonality and somatic hypermutation analyses gave comparable results. For future use in a routine diagnostic workflow, NGS-based approaches should be evaluated prospectively and an analysis of cost-effectiveness should be performed. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Navari, Mohsen, Etebari, Maryam, Ibrahimi, Mostafa, Leoncini, Lorenzo, Piccaluga, Pier Paolo

المساهمون: Navari, Mohsen, Etebari, Maryam, Ibrahimi, Mostafa, Leoncini, Lorenzo, Piccaluga, Pier Paolo

مصطلحات موضوعية: BART, BHRF1, Bam HI fragment H rightward open reading frame 1, BamHI-A rightward transcript, Epstein–Barr Viru, human lymphoma, microRNA, Epstein-Barr Virus Infection, Exosome, Gene Expression Regulation, Viral, Herpesvirus 4, Human, Lymphoma, RNA, Virus Latency

الوصف: Epstein-Barr virus (EBV) is a human γ-herpesvirus implicated in several human malignancies, including a wide range of lymphomas. Several molecules encoded by EBV in its latent state are believed to be related to EBV-induced lymphomagenesis, among which microRNAs-small RNAs with a posttranscriptional regulating role-are of great importance. The genome of EBV encodes 44 mature microRNAs belonging to two different classes, including BamHI-A rightward transcript (BART) and Bam HI fragment H rightward open reading frame 1 (BHRF1), with different expression levels in different EBV latency types. These microRNAs might contribute to the pathogenetic effects exerted by EBV through targeting self mRNAs and host mRNAs and interfering with several important cellular mechanisms such as immunosurveillance, cell proliferation, and apoptosis. In addition, EBV microRNAs can regulate the surrounding microenvironment of the infected cells through exosomal transportation. Moreover, these small molecules could be potentially used as molecular markers. In this review, we try to present an updated and extensive view of the role of EBV-encoded miRNAs in human lymphomas.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29649101; info:eu-repo/semantics/altIdentifier/wos/WOS:000434978700247; volume:19; issue:4; firstpage:1; lastpage:18; numberofpages:18; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; http://hdl.handle.net/11585/675923Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85045415462; https://www.mdpi.com/1422-0067/19/4/1168Test

الإتاحة: https://doi.org/10.3390/ijms19041168Test
http://hdl.handle.net/11585/675923Test
https://www.mdpi.com/1422-0067/19/4/1168Test

المؤلفون: GALIMBERTI, SARA, Luminari, Stefano, CIABATTI, ELENA, Grassi, Susanna, GUERRINI, FRANCESCA, Dondi, Alessra, Marcheselli, Luigi, Ladetto, Marco, Piccaluga, Pier Paolo, Gazzola, Anna, Mannu, Claudia, Monitillo, Luigia, Mantoan, Barbara, Giudice, Ilaria Del, Starza, Irene Della, Cavalli, Marzia, Arcaini, Luca, Tucci, Alessra, Palumbo, Giuseppe Alberto, Rigacci, Luigi, Pulsoni, Alessro, Vitolo, Umberto, Boccomini, Carola, Vallisa, Daniele, Bertoldero, Giovanni, Gaidano, Gianluca, Musto, Pellegrino, PETRINI, MARIO, Federico, Massimo

المساهمون: Galimberti, Sara, Luminari, Stefano, Ciabatti, Elena, Grassi, Susanna, Guerrini, Francesca, Dondi, Alessra, Marcheselli, Luigi, Ladetto, Marco, Piccaluga, Pier Paolo, Gazzola, Anna, Mannu, Claudia, Monitillo, Luigia, Mantoan, Barbara, Giudice, Ilaria Del, Starza, Irene Della, Cavalli, Marzia, Arcaini, Luca, Tucci, Alessra, Palumbo, Giuseppe Alberto, Rigacci, Luigi, Pulsoni, Alessro, Vitolo, Umberto, Boccomini, Carola, Vallisa, Daniele, Bertoldero, Giovanni, Gaidano, Gianluca, Musto, Pellegrino, Petrini, Mario, Federico, Massimo

مصطلحات موضوعية: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocol, Clinical Trials, Phase III as Topic, Female, Gene Dosage, Gene Rearrangement, Genes, bcl-2, Human, Immunoglobulin Heavy Chain, Lymphoma, Follicular, Male, Middle Aged, Neoplasm, Residual, Prognosi, ROC Curve, Real-Time Polymerase Chain Reaction, Treatment Outcome, Young Adult, Cancer Research, Oncology

الوصف: PURPOSE: The role of the minimal residual disease (MRD) in follicular lymphoma is still debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a prognostic role in patients receiving R-CHOP, R-FM, or R-CVP. EXPERIMENTAL DESIGN: DNAs from 415 patients among the 504 cases enrolled in the FOLL05 trial (NCT00774826) were centralized and assessed for the BCL2/IGH at diagnosis, at the end of treatment, and after 12 and 24 months. RESULTS: At diagnosis, the molecular marker was detected in 53% of cases. Patients without molecular marker or with a low molecular tumor burden (<1 × 10(-4) copies) showed higher complete remission (CR) rate and longer progression-free survival (PFS; 3-year PFS 80% vs. 59%; P = 0.015). PFS was significantly conditioned by the PCR status at 12 and 24 months, with 3-year PFS of 66% for MRD(-) cases versus 41% for those MRD(+) at 12 months (P = 0.015), and 84% versus 50% at 24 months (P = 0.014). The MRD negativity at 12 and 24 months resulted in an improved PFS both in CR and in partial remission (PR) patients (3-year PFS = 72% for cases CR/PCR(-) vs. 32% for those CR/PCR(+) vs. 62% for those PR/PCR(-) and 25% for patients in PR/PCR(+); P = 0.001). The prognostic value of MRD at 12 and 24 months of follow-up was confirmed also in multivariate analysis. CONCLUSIONS: In this study, standardized molecular techniques have been adopted and applied on bone marrow samples from a large cohort. Data reported show that the MRD detection is a powerful independent predictor of PFS in patients with follicular lymphoma receiving conventional chemoimmunotherapy.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25316810; info:eu-repo/semantics/altIdentifier/wos/WOS:000346418100021; volume:20; issue:24; firstpage:6398; lastpage:6405; numberofpages:8; journal:CLINICAL CANCER RESEARCH; https://hdl.handle.net/11568/760438Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84919687996; http://clincancerres.aacrjournals.org/content/20/24/6398.full.pdf+htmlTest

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-14-0407Test
https://hdl.handle.net/11568/760438Test
http://clincancerres.aacrjournals.org/content/20/24/6398.full.pdf+htmlTest

المؤلفون: LAGINESTRA, MARIA ANTONELLA, PICCALUGA, PIER PAOLO, FULIGNI, FABIO, Rossi, M., AGOSTINELLI, CLAUDIO, RIGHI, SIMONA, SAPIENZA, MARIA ROSARIA, MOTTA, GIOVANNA, GAZZOLA, ANNA, Mannu, C., Sabattini, E., Bacci, E., TABANELLI, VALENTINA, SAGRAMOSO SACCHETTI, CARLO ALBERTO, Barrese, T. Z., ETEBARI, MARYAM, MELLE, FEDERICA, CLO', ALBERTO, GIBELLINI, DAVIDE, Tripodo, C., Inghirami, G., Croce, C. M., PILERI, STEFANO

المساهمون: Laginestra, M.A, Piccaluga, P.P., Fuligni, F., Rossi, M., Agostinelli, C., Righi, S., Sapienza, M.R., Motta, G., Gazzola, A., Mannu, C., Sabattini, E., Bacci, E., Tabanelli, V., Sagramoso Sacchetti, C.A., Barrese, T.Z., Etebari, M., Melle, F., Clò, A., Gibellini, D., Tripodo, C., Inghirami, G., Croce, C.M., Pileri, S.A.

مصطلحات موضوعية: Female, Gene Expression Profiling, Human, Lymphoma, T-Cell, Peripheral, Male, MicroRNA, Oligonucleotide Array Sequence Analysi, RNA, Neoplasm, Gene Expression Regulation, Neoplastic, Oncology, Hematology

الوصف: Peripheral T-cell lymphomas not otherwise specified (PTCLs/NOS) are rare and aggressive tumours whose molecular pathogenesis and diagnosis are still challenging. The microRNA (miRNA) profile of 23 PTCLs/NOS was generated and compared with that of normal T-lymphocytes (CD4+, CD8+, naive, activated). The differentially expressed miRNA signature was compared with the gene expression profile (GEP) of the same neoplasms. The obtained gene patterns were tested in an independent cohort of PTCLs/NOS. The miRNA profile of PTCLs/NOS then was compared with that of 10 angioimmunoblastic T-cell lymphomas (AITLs), 6 anaplastic large-cell lymphomas (ALCLs)/ALK+ and 6 ALCLs/ALK-. Differentially expressed miRNAs were validated in an independent set of 20 PTCLs/NOS, 20 AITLs, 19 ALCLs/ALK- and 15 ALCLs/ALK+. Two hundred and thirty-six miRNAs were found to differentiate PTCLs/NOS from activated T-lymphocytes. To assess which miRNAs impacted on GEP, a multistep analysis was performed, which identified all miRNAs inversely correlated to different potential target genes. One of the most discriminant miRNAs was selected and its expression was found to affect the global GEP of the tumours. Moreover, two sets of miRNAs were identified distinguishing PTCL/NOS from AITL and ALCL/ALK-, respectively. The diagnostic accuracy of this tool was very high (83.54%) and its prognostic value validated.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25382608; info:eu-repo/semantics/altIdentifier/wos/WOS:000345905400003; volume:4; issue:11; firstpage:1; lastpage:13; numberofpages:13; journal:BLOOD CANCER JOURNAL; http://hdl.handle.net/11585/523427Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84927939976; http://www.nature.com/bcj/index.htmlTest

الإتاحة: https://doi.org/10.1038/bcj.2014.78Test
http://hdl.handle.net/11585/523427Test
http://www.nature.com/bcj/index.htmlTest

المؤلفون: Della Starza, Irene, Cavalli, Marzia, De Novi, Lucia Anna, Genuardi, Elisa, Mantoan, Barbara, Drandi, Daniela, Barbero, Daniela, Ciabatti, Elena, Grassi, Susanna, Gazzola, Anna, Mannu, Claudia, Agostinelli, Claudio, Piccaluga, Pier Paolo, Bomben, Riccardo, Degan, Massimo, Gattei, Valter, Guarini, Anna, Foà, Robin, Galimberti, Sara, Ladetto, Marco, Ferrero, Simone, Del Giudice, Ilaria

المساهمون: Della Starza, Irene, Cavalli, Marzia, De Novi, Lucia Anna, Genuardi, Elisa, Mantoan, Barbara, Drandi, Daniela, Barbero, Daniela, Ciabatti, Elena, Grassi, Susanna, Gazzola, Anna, Mannu, Claudia, Agostinelli, Claudio, Piccaluga, Pier Paolo, Bomben, Riccardo, Degan, Massimo, Gattei, Valter, Guarini, Anna, Foà, Robin, Galimberti, Sara, Ladetto, Marco, Ferrero, Simone, Del Giudice, Ilaria

مصطلحات موضوعية: FIL, MRD, PCR, PNQ sample, non-Hodgkin lymphoma, Bone Marrow, Clone Cell, Gene Rearrangement, B-Lymphocyte, Heavy Chain, Genes, Immunoglobulin, bcl-2, High-Throughput Nucleotide Sequencing, Human, Immunoglobulin Heavy Chain, Immunoglobulin Variable Region, Italy, Lymphoma, Non-Hodgkin, Neoplasm, Residual, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-bcl-2, Quality Assurance, Health Care, Reproducibility of Result, Translocation, Genetic

الوصف: In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD assessment. In 16 QC rounds between 2010 and 2017, the four laboratories received 208 bone marrow (BM) samples (126 FL; 82 MCL); 187 were analyzed, according to the EuroMRD Consortium guidelines, by both nested (NEST) polymerase chain reaction (PCR) and real-time quantitative (RQ) PCR for BCL2/IGH MBR or IGHV rearrangements. Here, we aimed at analyzing the samples that challenged the interlaboratory reproducibility and data interpretation. Overall, 156/187 BM samples (83%) were concordantly classified as NEST+/RQ+ or NEST-/RQ- by all the four laboratories. The remaining 31 samples (17%) resulted alternatively positive and negative in the interlaboratory evaluations, independently of the method and the type of rearrangement, and were defined "borderline" (brd) samples: 12 proved NEST brd/RQ brd, 7 NEST-/RQ brd, 10 NEST brd/RQ positive not quantifiable (PNQ), and 2 NEST brd/RQ-. Results did not change even increasing the number of replicates/sample. In 6/31 brd samples, droplet digital PCR (ddPCR) was tested and showed no interlaboratory discordance. Despite the high interlaboratory reproducibility in the MRD analysis obtained and maintained by the QC round strategy, samples with the lowest MRD levels can still represent a challenge: 17% (31/187) of our samples showed discordant results in interlaboratory assessments, with 6.4% (12/187) remained brd even applying the two methods. Thus, although representing a minority, brd samples are still problematic, especially when a clinically oriented interpretation of MRD results is required. Alternative, novel methods such as ddPCR and next-generation sequencing have the potential to overcome the current limitations.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31325190; info:eu-repo/semantics/altIdentifier/wos/WOS:000481391900001; volume:37; issue:4; firstpage:368; lastpage:374; numberofpages:7; journal:HEMATOLOGICAL ONCOLOGY; http://hdl.handle.net/2318/1728887Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85070737611

الإتاحة: https://doi.org/10.1002/hon.2652Test
http://hdl.handle.net/2318/1728887Test

المؤلفون: PICCALUGA, PIER PAOLO, AGOSTINELLI, CLAUDIO, Righi S, ZINZANI, PIER LUIGI, Pileri S.A.

المساهمون: Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA.

مصطلحات موضوعية: Lymphoma, T-Cell, Peripheral

الوصف: Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/17488672; info:eu-repo/semantics/altIdentifier/wos/WOS:000245411600023; volume:92; firstpage:566; lastpage:567; numberofpages:2; journal:HAEMATOLOGICA; http://hdl.handle.net/11585/51398Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-34547660727; http://www.haematologica.org/content/92/4/566Test

الإتاحة: https://doi.org/10.3324/haematol.10767Test
http://hdl.handle.net/11585/51398Test
http://www.haematologica.org/content/92/4/566Test

المؤلفون: Scarfò, Irene, Pellegrino, Elisa, Mereu, Elisabetta, Kwee, Ivo, Agnelli, Luca, Bergaggio, Elisa, Garaffo, Giulia, Vitale, Nicoletta, Caputo, Manuel, Machiorlatti, Rodolfo, Circosta, Paola, Abate, Francesco, Barreca, Antonella, Novero, Domenico, Mathew, Susan, Rinaldi, Andrea, Tiacci, Enrico, Serra, Sara, Deaglio, Silvia, Neri, Antonino, Falini, Brunangelo, Rabadan, Raul, Bertoni, Francesco, Inghirami, Giorgio, Piva, Roberto, Boi, Michela, Crescenzo, Ramona, Cuccuru, Giuditta, Gaudiano, Marcello, Lasorsa, Elena, Medico, Enzo, Messana, Katia, Spaccarotella, Elisa, Tabbò, Fabrizio, Todaro, Maria, Fornari, Alessandro, Chilosi, Marco, Zamò, Alberto, Facchetti, Fabio, Lonardi, Silvia, De Chiara, Anna, Fulciniti, Franco, Doglioni, Claudio, Ponzoni, Maurilio, Todoerti, Katia, De Wolf Peeters, Christiane, Tousseyn, Thomas, Van Loo, Peter, Geissinger, Eva, Muller Hermelink, Hans Konrad, Rosenwald, Andreas, Matolcsy, Andras, Piris, Miguel Angel, Rodriguez Pinilla, Maria E., AGOSTINELLI, CLAUDIO, PICCALUGA, PIER PAOLO, PILERI, STEFANO

المساهمون: Scarfò, Irene, Pellegrino, Elisa, Mereu, Elisabetta, Kwee, Ivo, Agnelli, Luca, Bergaggio, Elisa, Garaffo, Giulia, Vitale, Nicoletta, Caputo, Manuel, Machiorlatti, Rodolfo, Circosta, Paola, Abate, Francesco, Barreca, Antonella, Novero, Domenico, Mathew, Susan, Rinaldi, Andrea, Tiacci, Enrico, Serra, Sara, Deaglio, Silvia, Neri, Antonino, Falini, Brunangelo, Rabadan, Raul, Bertoni, Francesco, Inghirami, Giorgio, Piva, Roberto, Boi, Michela, Crescenzo, Ramona, Cuccuru, Giuditta, Gaudiano, Marcello, Lasorsa, Elena, Medico, Enzo, Messana, Katia, Spaccarotella, Elisa, Tabbò, Fabrizio, Todaro, Maria, Fornari, Alessandro, Chilosi, Marco, Zamò, Alberto, Facchetti, Fabio, Lonardi, Silvia, De Chiara, Anna, Fulciniti, Franco, Doglioni, Claudio, Ponzoni, Maurilio, Todoerti, Katia, Agostinelli, Claudio, Piccaluga, Pier Paolo, Pileri, Stefano, De Wolf-Peeters, Christiane, Tousseyn, Thoma, Van Loo, Peter, Geissinger, Eva, Muller-Hermelink, Hans Konrad, Rosenwald, Andrea, Matolcsy, Andra, Piris, Miguel Angel, Rodriguez-Pinilla, Maria E.

مصطلحات موضوعية: 5' Untranslated Region, Animal, Codon, Nonsense, Gene Expression Regulation, Neoplastic, HEK293 Cell, Human, Lymphoma, Large-Cell, Anaplastic, Mice, Inbred NOD, SCID, Transgenic, Molecular Sequence Data, Mutant Protein, NIH 3T3 Cell, RNA, Messenger, Receptor Protein-Tyrosine Kinase, Receptor, ErbB-4, Immunology, Biochemistry, Hematology, Cell Biology

الوصف: Anaplastic large-cell lymphoma (ALCL) is a clinical and biological heterogeneous disease that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALKnegative entities. To discover biomarkers and/or genes involved in ALK-negative ALCL pathogenesis, we applied the cancer outlier profile analysis algorithm to a gene expression profiling data set including 249 cases of T-cell non-Hodgkin lymphoma and normal T cells. Ectopic coexpression of ERBB4 and COL29A1 genes was detected in 24% of ALK-negative ALCL patients. RNA sequencing and 59 RNA ligase-mediated rapid amplification of complementary DNA ends identified 2 novel ERBB4-truncated transcripts displaying intronic transcription start sites. By luciferase assays, we defined that the expression of ERBB4-aberrant transcripts is promoted by endogenous intronic long terminal repeats. ERBB4 expression was confirmed at the protein level by western blot analysis and immunohistochemistry. Lastly, we demonstrated that ERBB4-truncated forms show oncogenic potentials and that ERBB4 pharmacologic inhibition partially controls ALCL cell growth and disease progression in an ERBB4-positive patient-derived tumorgraft model. In conclusion, we identified a new subclass of ALK-negative ALCL characterized by aberrant expression of ERBB4-truncated transcripts carrying intronic 59 untranslated regions.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26463425; info:eu-repo/semantics/altIdentifier/wos/WOS:000369285400012; volume:127; issue:2; firstpage:221; lastpage:232; numberofpages:12; journal:BLOOD; http://hdl.handle.net/11585/588477Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84955511756; http://www.bloodjournal.org/content/bloodjournal/127/2/221.full.pdfTest

الإتاحة: https://doi.org/10.1182/blood-2014-12-614503Test
http://hdl.handle.net/11585/588477Test
http://www.bloodjournal.org/content/bloodjournal/127/2/221.full.pdfTest

المؤلفون: AGOSTINELLI, CLAUDIO, STRACQUALURSI, LUISA, AGATI, PATRIZIA, FULIGNI, FABIO, SISTA, MARIA TERESA, FANTI, STEFANO, PICCALUGA, PIER PAOLO, BROCCOLI, ALESSANDRO, ARGNANI, LISA, ZINZANI, PIER LUIGI, PILERI, STEFANO, Gallamini, Andrea, Tripodo, Claudio, Biggi, Alberto, Vitolo, Umberto, Rigacci, Luigi, Merli, Francesco, Patti, Caterina, Romano, Alessandra, Levis, Alessandro, Trentin, Livio, Stelitano, Caterina, Borra, Anna, Hamilton Dutoit, Stephen, Kamper, Peter, Zaucha, Jan Maciej, Małkowski, Bogdan, Kulikowski, Waldemar, Tajer, Joanna, Subocz, Edyta, Rybka, Justyna, Steidl, Christian, Gascoyne, Randy D, D'Amore, Francesco

المساهمون: Agostinelli, Claudio, Gallamini, Andrea, Stracqualursi, Luisa, Agati, Patrizia, Tripodo, Claudio, Fuligni, Fabio, Sista, Maria Teresa, Fanti, Stefano, Biggi, Alberto, Vitolo, Umberto, Rigacci, Luigi, Merli, Francesco, Patti, Caterina, Romano, Alessandra, Levis, Alessandro, Trentin, Livio, Stelitano, Caterina, Borra, Anna, Piccaluga, Pier Paolo, Hamilton-Dutoit, Stephen, Kamper, Peter, Zaucha, Jan Maciej, Małkowski, Bogdan, Kulikowski, Waldemar, Tajer, Joanna, Subocz, Edyta, Rybka, Justyna, Steidl, Christian, Broccoli, Alessandro, Argnani, Lisa, Gascoyne, Randy D, D'Amore, Francesco, Zinzani, Pier Luigi, Pileri, Stefano A

مصطلحات موضوعية: lymphoma, PET, Hodgkin

الوصف: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27692305; info:eu-repo/semantics/altIdentifier/wos/WOS:000389070400008; volume:3; issue:10; firstpage:e467; lastpage:e479; numberofpages:13; journal:THE LANCET. HAEMATOLOGY; http://hdl.handle.net/11585/575959Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84994875454; http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026Test(16)30108-9/references

الإتاحة: https://doi.org/10.1016/S2352-3026Test(16)30108-9
http://hdl.handle.net/11585/575959Test
http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026Test(16)30108-9/references

المؤلفون: Odejide, Oreofe, Weigert, Oliver, Lane, Andrew A., Toscano, Dan, Lunning, Matthew A., Kopp, Nadja, Kim, Sunhee, Van Bodegom, Diederik, Bolla, Sudha, Schatz, Jonathan H., Teruya Feldstein, Julie, Hochberg, Ephraim, Louissaint, Abner, Dorfman, David, Stevenson, Kristen, Rodig, Scott J., Piccaluga, Pier Paolo, Jacobsen, Eric, Pileri, Stefano A., Harris, Nancy L., Horwitz, Steven M., Weinstock, David M., FERRERO, Simone, INGHIRAMI, Giorgio

المساهمون: Odejide, Oreofe, Weigert, Oliver, Lane, Andrew A., Toscano, Dan, Lunning, Matthew A., Kopp, Nadja, Kim, Sunhee, Van Bodegom, Diederik, Bolla, Sudha, Schatz, Jonathan H., Teruya-Feldstein, Julie, Hochberg, Ephraim, Louissaint, Abner, Dorfman, David, Stevenson, Kristen, Rodig, Scott J., Piccaluga, Pier Paolo, Jacobsen, Eric, Pileri, Stefano A., Harris, Nancy L., Ferrero, Simone, Inghirami, Giorgio, Horwitz, Steven M., Weinstock, David M

مصطلحات موضوعية: Adult, Aged, 80 and over, Cohort Studie, DNA Mutational Analysi, Female, Gene Frequency, Human, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Male, Middle Aged, Mutation, Immunology, Biochemistry, Hematology, Cell Biology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/24345752; info:eu-repo/semantics/altIdentifier/wos/WOS:000335839300010; volume:123; issue:9; firstpage:1293; lastpage:1296; numberofpages:4; journal:BLOOD; http://hdl.handle.net/2318/1639890Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84896617557; http://bloodjournal.hematologylibrary.org/content/123/9/1293.full-text.pdf+htmlTest

الإتاحة: https://doi.org/10.1182/blood-2013-10-531509Test
http://hdl.handle.net/2318/1639890Test
http://bloodjournal.hematologylibrary.org/content/123/9/1293.full-text.pdf+htmlTest

المؤلفون: Piccaluga, Pier Paolo, Tabanelli, Valentina, Pileri, Stefano A.

المساهمون: Piccaluga, Pier Paolo*, Tabanelli, Valentina, Pileri, Stefano A.

مصطلحات موضوعية: Gene expression profiling, High-throughput sequencing, Peripheral T-cell lymphoma, Tyrosine kinase, Antigens, CD20, Antineoplastic Agent, High-Throughput Nucleotide Sequencing, Human, Lymphoma, T-Cell, Peripheral, Molecular Targeted Therapy, NF-kappa B, Proto-Oncogene Proteins c-bcr, Transcriptome, Hematology

الوصف: Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK+ anaplastic T-cell lymphoma (ALCL), and ALK- ALCL-account for about 60 % of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK- ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK- ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK+ ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK+ and ALK- ALCLs. © 2014 The Japanese Society of Hematology.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/24481943; info:eu-repo/semantics/altIdentifier/wos/WOS:000333016900004; volume:99; issue:3; firstpage:219; lastpage:226; numberofpages:8; journal:INTERNATIONAL JOURNAL OF HEMATOLOGY; http://hdl.handle.net/11585/632841Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84897373303; http://www.springer.com/west/home?SGWID=4-102-70-173744104-0&changeHeader=trueTest

الإتاحة: https://doi.org/10.1007/s12185-014-1522-1Test
http://hdl.handle.net/11585/632841Test
http://www.springer.com/west/home?SGWID=4-102-70-173744104-0&changeHeader=trueTest